The company’s subsidiary "Eugia Pharma Specialities Ltd has received a 505(b)(2) NDA approval from the US Food Drug Administration (USFDA) for its Cyclophosphamide Injection 500 mg/2.5 mL and 1 g/5 mL vial,†Aurobindo Pharma said in a regulatory filing.Aurobindo Pharma gets USFDA nod for cancer treatment injection
The company’s subsidiary "Eugia Pharma Specialities Ltd has received a 505(b)(2) NDA approval from the US Food Drug Administration (USFDA) for its Cyclophosphamide Injection 500 mg/2.5 mL and 1 g/5 mL vial,†Aurobindo Pharma said in a regulatory filing.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The bank plans to raise up to Rs 500 crore by issue of equity shares to qualified institutional buyers through qualified institutional plac...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment